-
Electronic (PDF)
-
Site License
-
Enterprisewide
Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, December 2011, Pages: 86
Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global angina pectoris therapeutics market and identifies the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global angina pectoris therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The global angina pectoris therapeutics market, valued $9,655.4m in 2010, is estimated to reach a value of $12,707.4m by 2018, after increasing at a compound annual growth rate (CAGR) of 3.5%. The moderate growth in revenues is attributed to an increase in prevalence of the disease and the expected approval of first-in-class investigational therapies from the mature pipeline such as Generx, varespladib, rivoroxaban and otamixaban. However, if approved, these new products will be expensive as they possess novel mechanisms of action with significant improvements in safety and efficacy over the currently marketed drugs.
GlobalData has analysed that the current competition in the angina pectoris therapeutics market is weak and that the available treatment options are moderately successful in meeting the market demand. The products currently available in the market are associated with mediocre efficacy and safety profiles. Some of the serious side-effects associated with the current angina therapies are liver dysfunction, sexual dysfunction, headache, fatigue, bracycardia, worsening of heart failure, increased blood pressure and high mortality. In addition to this, the current treatments offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. Because the products currently in the market do not serve the unmet need, the market continues to present opportunities for stronger pipeline candidates. The unmet needs in the market are considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.
The angina pectoris developmental pipeline is strong with 16 products in various phases of clinical development. Phase III consists of five products. The pipeline is dominated by first-in-class molecules and certain late stage novel molecules are likely to offer better efficacy and safety over existing available drugs in the market.
Scope
The report provides information on the key drivers and challenges of the angina pectoris therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) angina pectoris therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as angiogenesis, cardiac If channel inhibitior, direct factor Xa inhibitor, phospholipase A2 inhibitor, cardiac myosin activator, sodium current blocker, stem cell therapy, substance P inhibitor, and VEGF-D gene therapy.
- Analysis of the current and future competition in the seven key countries angina pectoris therapeutics markets. Key market players covered are Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the angina pectoris therapeutics market.
- Analysis of key recent licensing and partnership agreements in the angina pectoris therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global angina pectoris therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global angina pectoris therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global angina pectoris therapeutics market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
1
1
1.1 List of Tables
1.2 List of Figures
2 Angina Pectoris Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Etiology of Angina Pectoris
2.3.2 Pathophysiology of Angina Pectoris
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Options
2.6.1 Lifestyle Changes
2.6.2 Medical Treatment
2.6.3 Medical Procedures
2.6.4 Cardiac Rehabilitation
2.7 GlobalData Pipeline Report Guidance
3 Angina Pectoris Therapeutics - Market Characterization
3.1 Angina Pectoris Therapeutics Market Size (2005 - 2010) - Global
3.2 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - Global
3.3 Angina Pectoris Therapeutics Market Size (2005 - 2010) - The US
3.4 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - The US
3.5 Angina Pectoris Therapeutics Market Size (2005 - 2010) - France
3.6 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - France
3.7 Angina Pectoris Therapeutics Market Size (2005 - 2010) - Germany
3.8 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - Germany
3.9 Angina Pectoris Therapeutics Market Size (2005 - 2010) - Italy
3.10 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - Italy
3.11 Angina Pectoris Therapeutics Market Size (2005 - 2010) - Spain
3.12 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - Spain
3.13 Angina Pectoris Therapeutics Market Size (2005 - 2010) - The UK
3.14 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - The UK
3.15 Angina Pectoris Therapeutics Market Size (2005 - 2010) - Japan
3.16 Angina Pectoris Therapeutics Market Forecast (2010 - 2018) - Japan
3.17 Drivers and Barriers for the Angina Pectoris Therapeutics Market
3.17.1 Drivers for the Angina Pectoris Therapeutics Market
3.17.2 Barriers for the Angina Pectoris Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Angina Pectoris Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Angina Pectoris Therapeutics Market
4.3.1 Sodium Channel Current Inhibitor
4.3.2 Nitrates
4.3.3 Beta-adrenergic Receptor Blockers (Beta Blockers)
4.3.4 Calcium Channel Blockers
4.3.5 Angiotensin Converting Enzyme Inhibitor (ACE inhibitors)
4.3.6 Statins
4.3.7 Selective If Channel Inhibitor
4.3.8 Glycoprotein IIb/IIIa inhibitor
4.4 Key Takeaway
5 Angina Pectoris Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Angina Pectoris Therapeutics - Pipeline Analysis by Clinical Phase of Development
5.3.1 Angina Pectoris Therapeutics - Phase III Clinical Pipeline
5.3.2 Angina Pectoris Therapeutics - Phase II Clinical Pipeline
5.3.3 Angina Pectoris Therapeutics - Phase I Clinical Pipeline
5.3.4 Angina Pectoris Therapeutics - Preclinical Phase Pipeline
5.4 Angina Pectoris Therapeutics - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Angina Pectoris Therapeutics - Most Promising Drugs in Clinical Development
5.7 Most Promising Drug Profiles
5.7.1 A-002 (Varespladib Methyl)
5.7.2 Capsaicin
5.7.3 Generx
5.7.4 Rivaroxaban
5.7.5 Otamixaban
5.8 Key Takeaway
6 Angina Pectoris Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Clinical Trials by Sponsors
6.6 Top Companies Participating in Angina Pectoris Therapeutics Clinical Trials
7 Angina Pectoris Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Angina Pectoris Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Anthera Pharmaceuticals
8.2.2 Cardium Therapeutics
8.2.3 Sanofi
8.2.4 Bayer HealthCare
8.2.5 CardioVascular BioTherapeutics
8.2.6 Cytokinetics
8.2.7 Ablynx
8.3 Other Companies in the Angina Pectoris Therapeutics Market
8.4 Key Takeaway
9 Angina Pectoris Therapeutics - Licensing & Partnership Deals
10 Angina Pectoris Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Characteristics of Various Types of Angina Pectoris
Table 2: Angina Pectoris Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 3: Angina Pectoris Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 4: Angina Pectoris Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 5: Angina Pectoris Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Table 6: Angina Pectoris Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 7: Angina Pectoris Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 8: Angina Pectoris Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 9: Angina Pectoris Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Table 10: Angina Pectoris Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 11: Angina Pectoris Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Table 12: Angina Pectoris Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 13: Angina Pectoris Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 14: Angina Pectoris Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 15: Angina Pectoris Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Table 16: Angina Pectoris Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 17: Angina Pectoris Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 18: Comparison of Major Marketed Products in the Angina Pectoris Therapeutics Market, 2011
Table 19: Angina Pectoris Therapeutics Market, Phase III and Regulatory Filed Pipeline, 2011
Table 20: Angina Pectoris Therapeutics Market, Phase II Pipeline, 2011
Table 21: Angina Pectoris Therapeutics Market, Phase I Pipeline, 2011
Table 22: Angina Pectoris Therapeutics Market, Pre-clinical and Discovery Phase Pipeline, 2011
Table 23: Angina Pectoris Therapeutics Market, Global, Most Promising Drugs in Clinical Development, 2011
Table 24: Angina Pectoris Therapeutics, Global, Clinical Trials, 2011
Table 25: Angina Pectoris Therapeutics, Global, Clinical Trials by Phase, 2011
Table 26: Angina Pectoris Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 27: Angina Pectoris Therapeutics, Global, Prominent Sponsors, 2011
Table 28: Angina Pectoris Therapeutics, Global, Overall Sponsors, 2011
Table 29: Angina Pectoris Therapeutics, Global, Top Ten Companies by Phase, 2011
Table 30: Anthera Pharmaceuticals - Angina Pectoris, Pipeline, 2011
Table 31: Cardium Therapeutics - Angina Pectoris, Pipeline, 2011
Table 32: Sanofi - Angina Pectoris, Pipeline, 2011
Table 33: Bayer HealthCare - Angina Pectoris, Pipeline, 2011
Table 34: CardioVascular BioTherapeutics - Angina Pectoris, Pipeline, 2011
Table 35: Cytokinetics - Angina Pectoris, Pipeline, 2011
Table 36: Ablynx - Angina Pectoris, Pipeline, 2011
Table 37: Other Companies in the Angina Pectoris Therapeutics Market
Table 38: Angina Pectoris Therapeutics, Global, Deals - 2011
1.2 List of Figures
Figure 1: Graphic Presentation of Angina Pectoris
Figure 2: Impact of Atherosclerosis on Arteries
Figure 3: Angina Pectoris Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 4: Angina Pectoris Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 5: Angina Pectoris Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Figure 6: Angina Pectoris Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 7: Angina Pectoris Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 8: Angina Pectoris Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 9: Angina Pectoris Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 10: Angina Pectoris Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 11: Angina Pectoris Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 12: Angina Pectoris Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 13: Angina Pectoris Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 14: Angina Pectoris Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 15: Angina Pectoris Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 16: Angina Pectoris Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 17: Angina Pectoris Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 18: Angina Pectoris Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 19: Opportunity and Unmet Need in the Angina Pectoris Therapeutics Market
Figure 20: Strategic Competitor Assessment of the Marketed Products in Angina Pectoris Therapeutics, 2011
Figure 21: Angina Pectoris Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 22: Angina Pectoris Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011
Figure 23: Technology Trends Analytics Framework, 2011
Figure 24: Technology Trends Analytics Framework - Description, 2011
Figure 25: Angina Pectoris Therapeutics, Global, Clinical Trials by Country, 2011
Figure 26: Angina Pectoris Therapeutics, Global, Clinical Trials by Phase (%), 2011
Figure 27: Angina Pectoris Therapeutics, Global, Clinical Trials by Status of Development (%), 2011
Figure 28: Angina Pectoris Therapeutics, Global, Prominent Sponsors (%), 2011
Figure 29: Angina Pectoris Therapeutics, Global, Overall Sponsors (%), 2011
Figure 30: Angina Pectoris Therapeutics, Global, Top Ten Companies by Phase, 2011
Figure 31: Angina Pectoris Therapeutics Market, Drivers and Restraints, 2011
Figure 32: Implications for Future Market Competition in the Angina Pectoris Therapeutics Market, 2011
Figure 33: Angina Pectoris Therapeutics Market, Global, Future Players, 2011
Figure 34: GlobalData Market Forecasting Model
GlobalData, the industry analysis specialist, has released its new report, “Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global angina pectoris therapeutics market and identifies the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global angina pectoris therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The Angina Pectoris Therapeutics Market is Expected to Show Moderate Growth Up to 2018
GlobalData has estimated the global angina pectoris therapeutics market to be worth $9,655.4m in 2010. It is expected to grow to $12,707.4m by 2018 at a compound annual growth rate (CAGR) of 3.5%. This growth can be primarily attributed to the rise in the number of patients undergoing treatment for angina pectoris and the expected approval of novel therapies such as Generx and varespladib, which are currently in late stage clinical development. However, if approved, these products are expected to be marketed at a premium price by their innovator companies when compared to other treatment options for angina. The reason why the launch of such products is at premium prices is attributed to the novel mechanism of action of these products which leads to a marked improvement in efficacy and safety over the currently marketed products. As a result the market penetration of these products is expected to remain low, limiting the growth rate of the angina pectoris therapeutics market. The forecast period will also witness patent expiries of major marketed products such as Lipitor (atorvastatin) in 2011, Aggrastat (tirofiban) in 2012, Angiomax/Angiox (bivalirudin) in 2015 in Europe and Crestor (rosuvastatin) in 2016. Such patent expiry of the major marketed products will attract generic versions of these drugs to the market. Therefore the angina pectoris therapeutics market is expected to witness moderate growth with a significant number of generics playing a major role in the forecasted period, which is similar to the present market scenario.
Anthera Pharmaceuticals
Cardium Therapeutics
Sanofi
Bayer HealthCare
CardioVascular BioTherapeutics
Cytokinetics
Ablynx
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
